Evofem Biosciences (NASDAQ:EVFM) (NASDAQ: EVFM) is a clinical-stage women’s health biotechnology company focused on the development and commercialization of novel products designed to address unmet needs in women’s sexual and reproductive health. The company’s core mission is to deliver products that empower women with safe, effective, and convenient options for contraception and the prevention of sexually transmitted infections. Evofem leverages proprietary formulation and drug delivery technologies to advance its pipeline candidates through clinical development and regulatory approval.
The company’s flagship product, Phexxi®, is a non-hormonal, on-demand vaginal gel that was approved by the U.S. Food and Drug Administration for use as a contraceptive. Phexxi works by maintaining the natural acidity of the vagina, creating an environment that is inhospitable to sperm. In addition to Phexxi, Evofem is advancing several pipeline programs, including next-generation contraceptive formulations and combined prevention candidates that aim to protect against both unintended pregnancy and sexually transmitted infections such as HIV. These candidates are designed for women seeking greater autonomy and choice in their reproductive health options.
Evofem Biosciences primarily serves the U.S. market through direct commercialization efforts and partnerships with specialty pharmaceutical distributors. The company is also exploring strategic collaborations and licensing agreements to extend its reach into select international markets. Clinical trials and regulatory activities are underway in various regions, reflecting Evofem’s commitment to building a global footprint in women’s health. Manufacturing and supply chain operations are managed via established contract development and manufacturing organizations, ensuring scalability and quality control.
Founded in 2013 and headquartered in San Diego, California, Evofem has assembled a leadership team with deep expertise in women’s health, clinical development, and commercial execution. John S. Modi serves as President and Chief Executive Officer, bringing more than 30 years of experience in pharmaceutical leadership roles. The company’s board and management team include seasoned professionals in regulatory affairs, biostatistics, and market access, all united by a shared goal to innovate in women’s sexual and reproductive health.
